XML 23 R16.htm IDEA: XBRL DOCUMENT
v3.24.3

Equity and Earnings per Share | 9 Months Ended
--- | ---
Nov. 02, 2024
Earnings Per Share [Abstract] |
Equity and Earnings per Share | 7. Equity and Earnings per Share The following table provides a reconciliation of the number of shares outstanding for basic and diluted earnings per share:
|  | For the three months ended |  |  | For the nine months ended |
|  | November 2, 2024 |  |  | October 28, 2023 |  |  | November 2, 2024 |  |  | October 28, 2023 |
(in thousands) |  |  |  |  |  |  |  |  |  |  |  |
Common stock outstanding: |  |  |  |  |  |  |  |  |  |  |  |
Basic weighted average common shares outstanding |  |  | 57,135 |  |  |  | 60,169 |  |  |  | 57,801 |  |  |  | 61,612 |
Common stock equivalents – stock options, restricted stock units and deferred stock (1) |  |  | — |  |  |  | 3,295 |  |  |  | 2,841 |  |  |  | 3,383 |
Diluted weighted average common shares outstanding |  |  | 57,135 |  |  |  | 63,464 |  |  |  | 60,642 |  |  |  | 64,995 |
(1) Common stock equivalents of 2.7 million for the third quarter of fiscal 2024 were excluded from the determination of diluted weighted average common shares outstanding due to the net loss reported for the third quarter of fiscal 2024. The following potential common stock equivalents were excluded from the computation of diluted earnings per share in each period, because the exercise price of such options was greater than the average market price per share of common stock for the respective periods or because the unearned compensation associated with stock options or restricted stock units had an anti-dilutive effect.
|  | For the three months ended |  |  | For the nine months ended |
|  | November 2, 2024 |  |  | October 28, 2023 |  |  | November 2, 2024 |  |  | October 28, 2023 |
(in thousands, except exercise prices) |  |  |  |  |  |  |  |  |  |  |  |
Stock options |  |  | 36 |  |  |  | 104 |  |  |  | 36 |  |  |  | 99 |
Restricted stock units and deferred stock |  |  | 770 |  |  |  | 41 |  |  |  | 347 |  |  |  | 17 |
Range of exercise prices of such options |  | $4.48-$6.59 |  |  | $4.48 - $6.59 |  |  | $4.48 - $6.59 |  |  | $4.48 - $6.59 |
The above options, which were outstanding at November 2, 2024, expire from November 10, 2024 to March 20, 2033. Excluded from the computation of basic and diluted earnings per share were 573,000 shares for the first three and nine months of fiscal 2024. These performance-based awards will be included in the computation of basic and diluted earnings per share if, and when, the respective performance targets are achieved. In addition, 466,225 shares and 435,568 shares of deferred stock at November 2, 2024 and October 28, 2023, respectively, were excluded from the computation of basic earnings per share. Shares of deferred stock are not considered issued and outstanding until the vesting date of the deferral period.

X
- Definition Equity and earnings per share. + References No definition available. + Details
Name: | dxlg_EquityAndEarningsPerShareTextBlock
Namespace Prefix: | dxlg_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration